Near infrared-responsive quinacrine-gold hybrid nanoparticles deregulate HSP-70/P300-mediated H3K14 acetylation in ER/PR+ breast cancer stem cells
Aim: This study aimed to determine if quinacrine-gold hybrid nanoparticles (QAuNPs) + near-infrared (NIR) deregulate HSP-70/P300 complex-mediated H3K14 acetylation in estrogen receptor/progesterone receptor (ER/PR+) breast cancer stem cells (CSCs). Materials & methods: Various cells and mouse-based systems were used as models. Results: QAuNP + NIR treatment reduced the nuclear translocation of HSP-70, affected the histone acetyltransferase activity of P300 and specifically decreased H3K14 acetylation in ER/PR+ breast CSCs. Finally, HSP-70 knockdown showed a reduction in P300 histone acetyltransferase activity, decreased H3K14 acetylation and inhibited activation of the TGF-β gene. Conclusion: This study revealed that QAuNP + NIR irradiation inhibits oncogenic activation of the TGF-β gene by decreasing H3K14 acetylation mediated through the HSP-70/P300 nuclear complex in ER/PR+ breast CSCs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Nanomedicine (London, England) - 19(2024), 7 vom: 28. März, Seite 581-596 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dash, Somya Ranjan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.03.2024 Date Revised 20.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/nnm-2023-0269 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36784141X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36784141X | ||
| 003 | DE-627 | ||
| 005 | 20240420232235.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240131s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2023-0269 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1381.xml |
| 035 | |a (DE-627)NLM36784141X | ||
| 035 | |a (NLM)38293827 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dash, Somya Ranjan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Near infrared-responsive quinacrine-gold hybrid nanoparticles deregulate HSP-70/P300-mediated H3K14 acetylation in ER/PR+ breast cancer stem cells |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.03.2024 | ||
| 500 | |a Date Revised 20.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: This study aimed to determine if quinacrine-gold hybrid nanoparticles (QAuNPs) + near-infrared (NIR) deregulate HSP-70/P300 complex-mediated H3K14 acetylation in estrogen receptor/progesterone receptor (ER/PR+) breast cancer stem cells (CSCs). Materials & methods: Various cells and mouse-based systems were used as models. Results: QAuNP + NIR treatment reduced the nuclear translocation of HSP-70, affected the histone acetyltransferase activity of P300 and specifically decreased H3K14 acetylation in ER/PR+ breast CSCs. Finally, HSP-70 knockdown showed a reduction in P300 histone acetyltransferase activity, decreased H3K14 acetylation and inhibited activation of the TGF-β gene. Conclusion: This study revealed that QAuNP + NIR irradiation inhibits oncogenic activation of the TGF-β gene by decreasing H3K14 acetylation mediated through the HSP-70/P300 nuclear complex in ER/PR+ breast CSCs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HSP-70 | |
| 650 | 4 | |a MCF-7-CSCs | |
| 650 | 4 | |a P300 | |
| 650 | 4 | |a T47D-CSCs | |
| 650 | 4 | |a TGF-β | |
| 650 | 4 | |a histone acetylation | |
| 650 | 4 | |a near-infrared | |
| 650 | 4 | |a quinacrine–gold hybrid nanoparticle | |
| 650 | 7 | |a Gold |2 NLM | |
| 650 | 7 | |a 7440-57-5 |2 NLM | |
| 650 | 7 | |a Histone Acetyltransferases |2 NLM | |
| 650 | 7 | |a EC 2.3.1.48 |2 NLM | |
| 650 | 7 | |a Quinacrine |2 NLM | |
| 650 | 7 | |a H0C805XYDE |2 NLM | |
| 650 | 7 | |a Transforming Growth Factor beta |2 NLM | |
| 700 | 1 | |a Das, Chinmay |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Biswajit |e verfasserin |4 aut | |
| 700 | 1 | |a Jena, Atala Bihari |e verfasserin |4 aut | |
| 700 | 1 | |a Paul, Subarno |e verfasserin |4 aut | |
| 700 | 1 | |a Sinha, Saptarshi |e verfasserin |4 aut | |
| 700 | 1 | |a Tripathy, Jasaswini |e verfasserin |4 aut | |
| 700 | 1 | |a Kundu, Chanakya Nath |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine (London, England) |d 2006 |g 19(2024), 7 vom: 28. März, Seite 581-596 |w (DE-627)NLM17228452X |x 1748-6963 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2024 |g number:7 |g day:28 |g month:03 |g pages:581-596 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/nnm-2023-0269 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2024 |e 7 |b 28 |c 03 |h 581-596 | ||